IGF-1 LR3: Evidence, Mechanism, Dosing & Legal Status

IGF-1 LR3 ("Long R3 IGF-1," LongR3-IGF-I) is an 83-amino-acid recombinant analog of human insulin-like growth factor 1, originally developed and still sold as a laboratory cell-culture reagent and promoted — without human evidence — for muscle hypertrophy and recovery.10 Its reputation in physique circles rests on one real engineered property; its proof in humans does not exist. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. IGF-1 LR3 is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature or in anecdotal use for completeness — not as recommendations. Self-administration of growth factors carries serious, potentially irreversible risk. Consult a licensed clinician before any health decision.

What is IGF-1 LR3 and how does it work?

IGF-1 LR3 is a synthetic, E. coli-expressed protein (~9.1-9.2 kDa) built on mature human IGF-1 with two engineered changes: glutamic acid at position 3 is replaced by arginine (the "R3"), and a 13-amino-acid N-terminal extension is fused to the N-terminus (the "Long").10 The molecule traces to the analog-engineering work of the Ballard, Francis and Wallace group at CSIRO Adelaide, who showed that Arg3 substitutions plus N-terminal extensions raise biological potency by weakening binding-protein affinity.1

The mechanism is the key to everything that follows. LR3 is an agonist of the type 1 IGF receptor (IGF-1R), a receptor tyrosine kinase widely expressed on skeletal muscle, bone, cardiac tissue and adipocytes; receptor engagement triggers the anabolic PI3K-Akt-mTOR axis (protein synthesis, anti-apoptosis) and the mitogenic Ras-MAPK axis.10 Critically, the LR3 modifications do not increase IGF-1R affinity versus native IGF-1 — receptor binding is comparable. The potency gain is purely pharmacokinetic.1

That pharmacokinetic trick is IGFBP evasion. In vivo, roughly 99 percent of native IGF-1 is bound to six IGF-binding proteins (IGFBPs), which block receptor access and govern clearance.11 The Arg3 and N-terminal-extension changes sharply lower IGFBP affinity, so in serum-containing assays where IGFBPs would neutralize native IGF-1, IGFBP-3 does not inhibit LR3 — the basis for its use as a cell-culture reagent (ED50 ~0.3-1.5 ng/mL in an MCF-7 proliferation assay).10 Native free IGF-1 has a circulating half-life of only about 10-15 minutes; LR3's IGFBP evasion extends functional exposure dramatically (commonly cited near 20-30 hours, though no validated human pharmacokinetics exist).1

What is the evidence by indication?

The bottom line up front: there are no human clinical trials of IGF-1 LR3 for any indication. Every efficacy claim below rests on animal or in-vitro data, or on uncontrolled anecdote. Human safety data for native IGF-1 (mecasermin) are extrapolated only and do not validate LR3.5

The anabolic rationale is real at the mechanistic level: IGF-1R to Akt/mTOR drives muscle protein synthesis and satellite-cell activity. In rodents, continuous LR3 infusion produced roughly 1.5 to 2-fold greater body-weight gain and improved feed efficiency than native IGF-1, and reduced muscle proteolysis about three-fold more than native IGF-1 in catabolic (dexamethasone-treated) rats — though LR3 was only barely equipotent for reversing carcass muscle loss in that same model.1 No human study has tested LR3 for muscle growth, strength or recovery, so the bodybuilding claims are graded D.5

The organ-growth data carry a warning. In guinea pigs, a 7-day LR3 infusion (120 µg/day) significantly increased the fractional weights of adrenals, gut, kidneys and spleen while overall body weight was unchanged — disproportionate visceral overgrowth rather than uniform somatic growth.2 The most rigorous recent test is also the most cautionary: in a 2024 study of growth-restricted fetal sheep, single-agent LR3 failed to improve fetal body weight or β-cell mass, reduced circulating branched-chain amino acids, and was associated with four fetal demises — all in LR3-treated animals — alongside ~42 percent drops in glucose and ~30 percent drops in oxygen; planned dose-escalation was halted for safety.3 You can read the underlying open-access report at PubMed Central. This is the clearest demonstration that LR3's potency is a liability, not just a benefit.

What doses appear in the literature?

Reported strictly as information, not a protocol. No human therapeutic dose, schedule or reconstitution standard has ever been established for IGF-1 LR3.5 In animals, rats received roughly 320 µg/day (normal) to 400 µg/day (catabolic) by osmotic pump or once- to twice-daily subcutaneous injection; guinea pigs received about 120 µg/day by continuous infusion; fetal sheep received roughly 1.17 to 6.6 µg per kg per hour by continuous IV.123 Anecdotal bodybuilding use, reported only for context, cites subcutaneous doses in the low microgram-per-day range (commonly ~20-50 µg/day) from lyophilized powder reconstituted in bacteriostatic water — figures that derive from forum and marketing material, not controlled study.5 Research-grade LR3 is shipped lyophilized and reconstituted per the laboratory datasheet, but black-market products have been documented to contain oxidized, degraded and even His-tagged variants, so identity and purity are not assured.5 By contrast, the approved native IGF-1 (mecasermin) is dosed by weight and given subcutaneously twice daily with food specifically to mitigate hypoglycemia.8

How safe is IGF-1 LR3?

The dominant acute hazard is hypoglycemia. Because IGF-1R signaling overlaps insulin signaling and LR3 also weakly binds the insulin receptor, dose-dependent hypoglycemia is the primary risk; in fetal sheep, LR3 produced ~42 percent glucose declines and contributed to fetal death.3 Hypoglycemia is also the most common labeled adverse reaction (~42 percent incidence) for the FDA-approved native IGF-1 mecasermin, which must be dosed with food and carries an overdose/acromegaly warning.8 LR3 infusion also lowered fetal oxygen tension by about 30 percent, and animal data show selective enlargement of viscera rather than balanced growth.2

The cancer-promotion concern is theoretical but evidence-anchored. IGF-1 is mitogenic and anti-apoptotic via IGF-1R, and large human epidemiology consistently links higher circulating IGF-1 to increased cancer risk: a UK Biobank cohort found higher IGF-1 associated with overall cancer risk in both sexes,13 an individual-participant meta-analysis tied IGF-1 to prostate cancer (OR ≈ 1.29),12 and a systematic review linked IGF-1 to prostate and premenopausal breast cancer.11 LR3 is engineered to drive sustained, unbuffered free-IGF-1R activation, so this risk is mechanistically plausible, though no study has measured cancer outcomes from LR3 specifically.14 Contraindicated or cautioned populations — extrapolated from the native IGF-1 label, since no LR3-specific data exist — include active or prior malignancy, children with closed epiphyses, pregnancy and lactation, and anyone with labile glucose; additive hypoglycemia with insulin or sulfonylureas is expected.8 From a functional, root-cause perspective, the IGFBP system exists precisely to throttle IGF-1 delivery, and forcing supraphysiologic, unbuffered IGF-1R activation runs directly against that regulation.

What is the FDA and WADA status in 2026?

IGF-1 LR3 is not approved by the FDA for any human or veterinary indication and is marketed strictly "for research use only." It is not an FDA-recognized compounding bulk substance and cannot lawfully be compounded for human use under 503A or 503B.5 The only FDA-approved IGF-1 product is native recombinant IGF-1 — mecasermin (Increlex) — approved for the narrow pediatric indication of severe primary IGF-1 deficiency; LR3 is a different, modified molecule not covered by that approval.89 It is not a DEA-scheduled controlled substance, being governed instead by FDA unapproved-new-drug provisions and FTC marketing rules.5

For athletes the picture is unambiguous. IGF-1 and its analogues — explicitly including LongR3-IGF-I — are prohibited at all times, in and out of competition, under WADA Section S2 (peptide hormones, growth factors, related substances and mimetics), classified as non-specified substances carrying the strictest sanctions.7 Validated detection is established: immunopurification plus high-resolution mass spectrometry distinguishes LongR3-IGF-I, R3-IGF-I and Des(1-3)-IGF-I from native IGF-1 in blood, with adjunct biological-passport monitoring.56

Bottom line. IGF-1 LR3 is a laboratory reagent, not a medicine. Its one genuinely validated property — IGFBP-evading, long-acting IGF-1R agonism — makes it useful in cell culture and gives it a real anabolic signal in animals (graded C), but that same potency caused visceral overgrowth, suppressed the endogenous IGF axis, severe hypoglycemia and hypoxemia, and fetal death in the most rigorous recent animal work, where it also failed to rescue growth. For human muscle growth or recovery the evidence is graded D — anecdotal and mechanistic only, with zero human trials. It is FDA-unapproved, sold "research use only," and WADA-prohibited at all times with established detection. Regulatory and evidence facts here are current as of June 2026 and should be re-verified for later developments.